An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women with High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Sep 2022 Results assessing safety, immunogenicity and efficacy of therapeutic DNA vaccine published in the Clinical Cancer Research
03 Apr 2019 Interim Results of 6 month data from phase1/2a trial assessing safety/tolerability, immunogenicity and efficacy of VB10.16 in patients with human papillomavirus (HPV) presented at the 110th Annual Meeting of the American Association for Cancer Research
25 Mar 2019 12-months results from the phase IIa part presented in the Vaccibody Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com